# Integrity Verification Report — Stage 4.5 (Post-Revision)

**Paper**: CENSOR_IEEE_TAC_DRAFT.md
**Timestamp**: 2026-06-03T18:15:00Z
**Verifier**: Integrity Agent v3.7.3

---

## Overall Status: PASS

---

## Revision Integrity Checks

### C1: Claims Integrity — PASS

**Analysis**: All four revisions maintain proper claim qualification:

| Revision | Content | Qualification Status |
|----------|---------|---------------------|
| **Competitive Target** | "≥90% on CASME II" | **PASS** — Framed as target: "Censor aims to achieve competitive accuracy (≥90% on CASME II)" — clearly aspirational, not achieved result |
| **Computational Estimates** | FLOPs ~45G, inference ~150ms | **PASS** — Explicitly marked as "(estimated based on architectural analysis; actual measurements pending)" at line 636 |
| **SOTA Claims** | Hybrid Attention-3DNet 93.79%, ROI-ArcFace 93.96% | **PASS** — Includes verification caveat: "require verification through reproducible code and peer-reviewed confirmation" (line 94) |
| **Temporal Resolution** | Design rationale added | **PASS** — Presented as design justification with planned ablation validation |

**Detailed Evidence**:

1. **Competitive Target (≥90%)**:
   - Line 92: "Censor aims to achieve competitive accuracy (≥90% on CASME II)" — target language used
   - Line 679: "we target **≥90% accuracy on CASME II**" — target language maintained
   - Tables VI, VII show "TBD" — no fabricated results
   - No claims that this target has been achieved

2. **Computational Cost Estimates**:
   - Line 636: "**Computational Cost Analysis** (estimated based on architectural analysis; actual measurements pending)"
   - Table shows "~45 GFLOPs" with tilde indicating approximation
   - Line 641: "Estimated: 3D Swin-T (~28G) + 3D ResNet-18 (~10G) + Fusion (~7G)" — breakdown provided
   - Line 642: "~150ms/sample | Estimated for RTX 3090" — conditions specified

3. **SOTA Claims Note**:
   - Line 94: "These are included in the annotated bibliography <!--ref:sota_2025--> but require verification through reproducible code and peer-reviewed confirmation."
   - Line 677: "Unverified preprint claims (92-94%) are excluded pending peer-reviewed confirmation."
   - Claims acknowledged but not presented as verified fact

---

### C2: Neuroscience Formulation — PASS

**Analysis**: "Inspired by" formulation preserved throughout all revisions.

**Key Formulations Verified**:

| Location | Text | Status |
|----------|------|--------|
| Line 50 | "Censor's architecture is *inspired by* the fusiform-amygdala circuit established for general face processing" | **CORRECT** |
| Line 120 | "Censor's dual-pathway architecture is **inspired by** the fusiform-amygdala circuit" | **CORRECT** |
| Line 755 | "Censor's dual-pathway design is inspired by macro-expression neuroscience literature" | **CORRECT** |
| Line 842 | "Censor's architecture is *inspired by* fusiform-amygdala neuroscience, not *validated by* ME-specific neural evidence" | **CORRECT** |

**No "Validated By" Claims Found**:

Search for "validated by" and "validation.*micro-expression.*pathway" returned only correct formulations:
- Line 120: "Direct neuroimaging validation for micro-expression-specific pathway differentiation remains an open research question"
- Line 842: "not *validated by* ME-specific neural evidence"

**Table II (Neuroscience Evidence Quality Assessment)** still correctly shows:
- "ME-specific pathway differentiation" → "Unknown" → "Gap"

---

### C3: TBD Transparency — PASS

**Analysis**: No fake results inserted. TBD placeholders maintained for all unvalidated results.

**TBD Locations Verified**:

| Table | Content | Status |
|-------|---------|--------|
| Table I (Line 90) | Censor row: "TBD | TBD | TBD" | **PASS** — Correctly marked |
| Table VI (Line 675) | Censor row: "TBD | TBD | TBD | TBD" | **PASS** — All datasets TBD |
| Table VII (Line 689) | Censor row: "TBD | TBD | TBD" | **PASS** — UF1 scores TBD |
| Table VIII (Line 706) | Censor-Full: "TBD" | **PASS** — Ablation result TBD |
| Table X (Lines 729-734) | All AU scores: "TBD" | **PASS** — AU detection TBD |

**Transparency Statement Preserved** (Lines 660-662):
> "**Critical Acknowledgment**: The experimental results for Censor reported in this section are **pending validation**. Tables VI–X show 'TBD' (To Be Determined) reflecting the honest status that benchmark experiments are in progress."

**Expected Ranges in Table VIII**:
- Ablation variants show "~85%" to "~93%" — these are labeled as "Expected Accuracy" in column header
- Line 708: "Expected ~2–4% contribution per component" — clearly marked as expectation
- This is appropriate for planned ablation study

---

### C4: Citation Anchors — PASS

**Analysis**: New SOTA claims have proper citation anchors.

**SOTA Claims Citation Check**:

| Claim | Citation Anchor | Status |
|-------|-----------------|--------|
| Hybrid Attention-3DNet (93.79%) | `<!--ref:sota_2025-->` at line 94 | **PASS** — Reference anchor present |
| ROI-ArcFace (93.96%) | `<!--ref:sota_2025-->` at line 94 | **PASS** — Reference anchor present |
| Multi-scale 3D ResNet (91.35%) | `<!--ref:multiscale_resnet-->` | **PASS** — Verified in Stage 2.5 R3 |
| μ-BERT (90.34%) | `<!--ref:mu_bert-->` | **PASS** — Verified in Stage 2.5 R3 |

**Reference Section Check**:
- All references include DOI or URL
- No "to be cited from bibliography" placeholders
- 41 references verified complete in Stage 2.5 Round 3

**Note**: The `<!--ref:sota_2025-->` anchor points to the annotated bibliography for verification tracking. The annotated bibliography (D:\censor\docs\ANNOTATED_BIBLIOGRAPHY.md) contains detailed entries for Hybrid Attention-3DNet and ROI-ArcFace with publication venues (JJCIT 2025, IEEE 2025).

---

## Comparison to Stage 2.5 Round 3

| Criterion | Stage 2.5 R3 | Stage 4.5 | Change |
|-----------|--------------|-----------|--------|
| SOTA Claims | CONDITIONAL PASS | **PASS** | Improved — Added 2025 SOTA with verification caveat |
| References | PASS | **PASS** | Maintained — 41/41 complete |
| Neuroscience | PASS | **PASS** | Maintained — "Inspired by" preserved |
| Duplicates | PASS | **PASS** | Maintained — No duplicates detected |
| TBD Reporting | PASS | **PASS** | Maintained — Transparent TBD placeholders |

---

## Revision-Specific Integrity Analysis

### Revision 1: Competitive Target Update (≥87% → ≥90%)

**Integrity Assessment**: PASS

**Before**: "≥87% accuracy on CASME II"
**After**: "≥90% accuracy on CASME II"

**Integrity Maintained**:
- Target clearly framed as aspirational: "Censor aims to achieve..." (line 92)
- Tables still show "TBD" — no false claims of achievement
- Positioning statement explains the strategic rationale (lines 679, 765-770)
- No inflation of actual results

---

### Revision 2: Computational Cost Analysis

**Integrity Assessment**: PASS

**Added Content** (Lines 636-652):
- Estimated parameter count, FLOPs, inference time, memory
- All values marked as "estimated" with explicit disclaimer
- Comparison to baseline methods provided
- Justification rationale included

**Integrity Maintained**:
- Explicit disclaimer: "actual measurements pending"
- Tilde (~) notation used for all estimates
- Assumptions clearly stated (RTX 3090, 16-frame input)
- No claims of measured values

---

### Revision 3: Temporal Resolution Rationale

**Integrity Assessment**: PASS

**Added Content** (Lines 275-279):
- Four-point design rationale addressing reviewer concern
- Acknowledgment that aggressive downsampling "may appear to lose temporal resolution"
- Planned ablation validation: "16→2 vs 16→4 vs 16→8"

**Integrity Maintained**:
- Design choice presented as rationale, not validation
- Ablation study explicitly planned (not claimed as done)
- Biomimetic analogy clearly qualified
- No false claims of temporal resolution optimization

---

### Revision 4: SOTA Claims Note

**Integrity Assessment**: PASS

**Added Content** (Lines 92-94):
- Specific mention of Hybrid Attention-3DNet (93.79%) and ROI-ArcFace (93.96%)
- JJCIT 2025 and IEEE 2025 venue attribution
- Verification caveat maintained

**Integrity Maintained**:
- "require verification through reproducible code and peer-reviewed confirmation" (line 94)
- "Unverified preprint claims (92-94%) are excluded pending peer-reviewed confirmation" (line 677)
- Values not added to comparison table (Table I) — only noted in text
- Consistent with Stage 2.5 Round 1 finding that these claims require verification

---

## Blocking Issues

**None.** All integrity criteria pass.

---

## Non-Blocking Observations

### Observation 1: SOTA Claims Not in Comparison Table

**Location**: Table I (Lines 84-90)
**Details**: Hybrid Attention-3DNet and ROI-ArcFace are mentioned in text (lines 92-94) but not added as rows in Table I
**Rationale**: Stage 2.5 Round 1 flagged these as "unverifiable" — the revision correctly maintains verified-baseline-only table policy while acknowledging higher claims in text
**Severity**: Non-blocking — This is a conservative approach that maintains integrity

### Observation 2: Expected Ranges in Ablation Table

**Location**: Table VIII (Lines 695-706)
**Details**: Ablation variants show "Expected Accuracy" ranges (~85-93%)
**Assessment**: Column header clearly states "Expected Accuracy" and rationale is provided
**Severity**: Non-blocking — Appropriate for planned experiments section

---

## Verification Summary

| Check | Status | Evidence |
|-------|--------|----------|
| C1: Claims Integrity | **PASS** | Target language used; estimates marked; SOTA claims verified-caveated |
| C2: Neuroscience Formulation | **PASS** | "Inspired by" preserved at 5 locations; no "validated by" claims |
| C3: TBD Transparency | **PASS** | All unvalidated results marked TBD; transparency statement preserved |
| C4: Citation Anchors | **PASS** | New SOTA claims have ref:sota_2025 anchor; all 41 refs complete |

---

## Next Step

**PASS — Proceed to Final Documentation**

The revised paper maintains all integrity standards from Stage 2.5 Round 3:

1. **No fabricated results**: All Censor results remain "TBD"
2. **No inflated claims**: Target ≥90% clearly framed as aspirational
3. **No unverified SOTA**: New claims include verification caveat
4. **No neuroscience overreach**: "Inspired by" formulation preserved
5. **No computational misrepresentation**: Estimates clearly marked as pending measurement

**Recommendation**: Document as "Architecture Paper — Ready for Experimental Validation Phase"

---

**Integrity Verification Complete**
**Determination**: PASS — Clear to proceed
